Varicose Ulcer
Conditions
Brief summary
The purpose of this study is to evaluate the product performance of a new adjustable compression system for the treatment of venous leg ulcers.
Detailed description
The purpose of this study is to evaluate the product performance of a new adjustable compression system for the treatment of venous leg ulcers. The new compression system consists of a compression stocking and and adjustable compression sleeve. It will be used over primary dressings to provide compression that is beneficial to the healing of venous leg ulcers.
Interventions
DEVICE3M™ Coban™ Custom Fit Compression System
3M Coban™ Fit is a compression system that consists of two components: 1. A Compression Stocking and 2. Coban™ Fit Sleeve. The stocking provides compression to the foot and improves wearing comfort in the calf area under the sleeve. The compression sleeve is intended to provide the therapeutic compression to the calf, with the initial fitting to be done by a health-care professional. The compression sleeve is customized according to the anatomy of the patient's leg; both components are designed to be used together.
DEVICEProfore
PROFORE is a multi-layer compression bandaging system developed to apply sustained graduated compression for the management of venous leg ulcers and associated conditions. Multi-layer compression bandaging is the first choice in treatment for venous leg ulcers.
Sponsors
3M
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Is the subject 21 years or older? 2. Does the subject have an active venous leg ulceration? If multiple ulcers are present, the investigator will need to select a single ulcer of the study leg that is \> 2cm apart from any other ulcer? 3. Does the subject have an ulcer size between 1cm2 and 12cm2? 4. Does the subject have an ABPI between 0.8 and 1.3 that was taken within the past 28 days? 5. Is the subject ambulatory? 6. Is the subject or family member willing to self-manage the venous leg ulcer therapy at home in collaboration with the medical staff, including the ability to properly readjust the closure straps as indicated by tension indicators, and apply new dressings when needed? 7. Is the subject able to understand questionnaire items and action items (e.g., Subject Diary)? 8. Is the subject willing to give written informed consent, including permission to take photographs of the study leg?
Exclusion criteria
1. Does the subject have severe arterial occlusive disease? 2. Does the subject have decompensated heart insufficiency NYHA Class IV, ACC.AHA Stage D? 3. Does the subject have septic phlebitis? 4. Does the subject have severe deep vein thrombosis (phlegmasia cerulea dolens) and other conditions contraindicated according to established guidelines and local procedures? 5. Does the subject have known hypersensitivity to any of the component materials? 6. Does the subject have a suspected clinical infection of the ulcer or any other systemic infection (requiring antibiotics)? 7. Is the subject scheduled for surgery for the ulcer during the 12 weeks following inclusion? 8. Does the subject have a hospital stay planned for the 12 weeks following inclusion? 9. Does the subject have a suspected or confirmed cancerous ulceration? 10. Does the subject have severe peripheral sensitive neuropathy? 11. Is the subject participating in any other prospective study interfering with this study? 12. Does the subject have any medical condition which in the professional opinion of the investigator disqualifies the subject from enrollment into the study? 13. Does the subject have a history of noncompliance to therapies?
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy endpoint is the number of ulcers achieving complete closure (100% epithelialization) after 12 weeks | 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Wound area reduction and relative wound area reduction at weeks 4, 8, and 12. | Up to 12 weeks |
| Relative wound area reduction >/= 40% at Week 4 | 4 weeks |
| Time to complete closure | 1-12 weeks |
| Occurrence of treatment-related adverse events | 0-12 weeks |
| Occurrence of treatment-related drop-outs | 0-12 weeks |
Countries
Canada, United States
Outcome results
None listed